永久性心脏起搏器治疗缓慢性心律失常45例

目的观察永久性心脏起搏器治疗缓慢性心律失常近中期疗效及安全性。方法自2004年2月至2008年6月，本院接受永久性心脏起搏器植入术45例，回顾分析患者资料。观察术后生理性起搏组（18例）与非生理性起搏组（27例）临床症状缓解情况、并发症、脑卒中、新发房颤、死亡等事件。结果两组患者术后症状明显改善。术后囊袋血肿2例。两组各1例发生脑梗死，脑卒中发生率差异无统计学意义（x^2=0．1962，P〉0．05）。两组均无新发房颤病例。非生理性起搏组死亡1例，死因心室颤动。结论永久性心脏起搏器治疗缓慢性心律失常可显著改善临床症状，提高生活质量，近中期较安全。

Permanent cardiac pacemaker treatment bradyarrythmia 45 patients

Objective To explore the efficacy and safety of ADV and LMV effect on the chronic hepa-titis patients with Hepatitis B Virus LAM-resistant. Methods The ro11 ed 68 chronic hepatitis patients with Hepatitis B Virus LAM-resistant were randomly divided into two groups:The control group( A group,34 cases) and the treatment group( group B ,34 cases), The patients in control group received lamivudineat therapy at a dose of 100 mg daily;however the patients in treatment group received lamivudineat 100 mg daily and adefovir 10 mg daily therapy, and the course of treatment was 3 months. To detect Liver and Kidney function, HBV DNA, HBsAg, and to observe the change pathogenetic condition and side effect. Results After 3 months, the treatment group's ALT and HBV DNA level decreased, Which were lower than that of group A (P<0.05), The ALT level came down to mormal in the treatment group was biger than that of group A(P<0.05). and HBV DNA level be-tween two groups was inverse. Conclusion ADV and LMV is effective and safe for the chronic hepatitis patients with Hepatitis B Virus LAM-resistant.